Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Outstanding Challenges in the Transferability of Ecological Models.

Yates KL, Bouchet PJ, Caley MJ, Mengersen K, Randin CF, Parnell S, Fielding AH, Bamford AJ, Ban S, Barbosa AM, Dormann CF, Elith J, Embling CB, Ervin GN, Fisher R, Gould S, Graf RF, Gregr EJ, Halpin PN, Heikkinen RK, Heinänen S, Jones AR, Krishnakumar PK, Lauria V, Lozano-Montes H, Mannocci L, Mellin C, Mesgaran MB, Moreno-Amat E, Mormede S, Novaczek E, Oppel S, Ortuño Crespo G, Peterson AT, Rapacciuolo G, Roberts JJ, Ross RE, Scales KL, Schoeman D, Snelgrove P, Sundblad G, Thuiller W, Torres LG, Verbruggen H, Wang L, Wenger S, Whittingham MJ, Zharikov Y, Zurell D, Sequeira AMM.

Trends Ecol Evol. 2018 Oct;33(10):790-802. doi: 10.1016/j.tree.2018.08.001. Epub 2018 Aug 27. Review.

2.

Host plant defense signaling in response to a coevolved herbivore combats introduced herbivore attack.

Woodard AM, Ervin GN, Marsico TD.

Ecol Evol. 2012 May;2(5):1056-64. doi: 10.1002/ece3.224.

3.
4.

Influence of a dominant macrophyte, Juncus effusus, on wetland plant species richness, diversity, and community composition.

Ervin GN, Wetzel RG.

Oecologia. 2002 Feb;130(4):626-636. doi: 10.1007/s00442-001-0844-x. Epub 2002 Feb 1.

PMID:
28547266
5.

1,4-Benzodiazepine peripheral cholecystokinin (CCK-A) receptor agonists.

Sherrill RG, Berman JM, Birkemo L, Croom DK, Dezube M, Ervin GN, Grizzle MK, James MK, Johnson MF, Queen KL, Rimele TJ, Vanmiddlesworth F, Sugg EE.

Bioorg Med Chem Lett. 2001 May 7;11(9):1145-8.

PMID:
11354363
6.
7.
8.

Optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists.

Henke BR, Aquino CJ, Birkemo LS, Croom DK, Dougherty RW Jr, Ervin GN, Grizzle MK, Hirst GC, James MK, Johnson MF, Queen KL, Sherrill RG, Sugg EE, Suh EM, Szewczyk JW, Unwalla RJ, Yingling J, Willson TM.

J Med Chem. 1997 Aug 15;40(17):2706-25.

PMID:
9276016
9.

Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity (II): Optimization of the C3 amino substituent.

Hirst GC, Aquino C, Birkemo L, Croom DK, Dezube M, Dougherty RW Jr, Ervin GN, Grizzle MK, Henke B, James MK, Johnson MF, Momtahen T, Queen KL, Sherrill RG, Szewczyk J, Willson TM, Sugg EE.

J Med Chem. 1996 Dec 20;39(26):5236-45.

PMID:
8978852
10.

3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines: CCK-A agonists that demonstrate oral activity as satiety agents.

Henke BR, Willson TM, Sugg EE, Croom DK, Dougherty RW Jr, Queen KL, Birkemo LS, Ervin GN, Grizzle MK, Johnson MF, James MK.

J Med Chem. 1996 Jul 5;39(14):2655-8. No abstract available.

PMID:
8709093
11.

Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist "trigger".

Aquino CJ, Armour DR, Berman JM, Birkemo LS, Carr RA, Croom DK, Dezube M, Dougherty RW Jr, Ervin GN, Grizzle MK, Head JE, Hirst GC, James MK, Johnson MF, Miller LJ, Queen KL, Rimele TJ, Smith DN, Sugg EE.

J Med Chem. 1996 Jan 19;39(2):562-9.

PMID:
8558528
12.

Several roles of CCKA and CCKB receptor subtypes in CCK-8-induced and LiCl-induced taste aversion conditioning.

Mosher JT, Johnson MF, Birkemo LS, Ervin GN.

Peptides. 1996;17(3):483-8.

PMID:
8735976
13.

Modification of receptor selectivity and functional activity in cholecystokinin peptoid ligands.

Dezube M, Sugg EE, Birkemo LS, Croom DK, Dougherty RW Jr, Ervin GN, Grizzle MK, James MK, Johnson MF, Mosher JT, et al.

J Med Chem. 1995 Aug 18;38(17):3384-90.

PMID:
7650691
14.

The effects of anorectic and aversive agents on deprivation-induced feeding and taste aversion conditioning in rats.

Ervin GN, Birkemo LS, Johnson MF, Conger LK, Mosher JT, Menius JA Jr.

J Pharmacol Exp Ther. 1995 Jun;273(3):1203-10.

PMID:
7791092
15.
16.

Cholecystokinin and satiety: a time line.

Ervin GN.

Ann N Y Acad Sci. 1994 Mar 23;713:232-5. Review. No abstract available.

PMID:
8185164
19.

Use of conditioned taste aversion as a conflict model: effects of anxiolytic drugs.

Ervin GN, Cooper BR.

J Pharmacol Exp Ther. 1988 Apr;245(1):137-46.

PMID:
2896235
20.

Interactions of neurotensin with dopamine-containing neurons in the central nervous system.

Ervin GN, Nemeroff CB.

Prog Neuropsychopharmacol Biol Psychiatry. 1988;12 Suppl:S53-69. Review.

PMID:
3074341
21.
22.

Evidence that taste aversion learning induced by l-5-hydroxytryptophan is mediated peripherally.

Ervin GN, Carter RB, Webster EL, Moore SI, Cooper BR.

Pharmacol Biochem Behav. 1984 May;20(5):799-802.

PMID:
6610880
23.

Thyrotropin-releasing hormone and amphetamine produce different patterns of behavioral excitation in rats.

Ervin GN, Schmitz SA, Nemeroff CB, Prange AJ Jr.

Eur J Pharmacol. 1981 Jun 10;72(1):35-43.

PMID:
6790295
24.

Neurotensin blocks certain amphetamine-induced behaviours.

Ervin GN, Birkemo LS, Nemeroff CB, Prange AJ Jr.

Nature. 1981 May 7;291(5810):73-6.

PMID:
7231526
25.

Alterations in nociception and body temperature after intracisternal administration of neurotensin, beta-endorphin, other endogenous peptides, and morphine.

Nemeroff CB, Osbahr AJ 3rd, Manberg PJ, Ervin GN, Prange AJ Jr.

Proc Natl Acad Sci U S A. 1979 Oct;76(10):5368-71.

26.

Hypothalamic and locus coeruleus self-stimulation are decreased by cholecystokinin.

Kornblith CL, Ervin GN, King RA.

Physiol Behav. 1978 Dec;21(6):1037-41. No abstract available.

PMID:
552067
27.
28.

Growth, endocrinological and behavioral deficits after monosodium L-glutamate in the neonatal rat: possible involvement of arcuate dopamine neuron damage.

Nemeroff CB, Grant LD, Bissette G, Ervin GN, Harrell LE, Prange AJ Jr.

Psychoneuroendocrinology. 1977;2(2):179-96. No abstract available.

PMID:
601168
29.

Abnormal open field behavior after anterolateral hypothalamic injection of 6-hydroxydopamine.

Young RC, Ervin GN, Smith GP.

Pharmacol Biochem Behav. 1976 Nov;5(5):565-70.

PMID:
1019187
30.

The roles of monoamine neural systems in the anorexia induced by(+)-amphetamine and related compounds.

Hollister AS, Ervin GN, Cooper BR, Breese GR.

Neuropharmacology. 1975 Oct;14(10):715-23. No abstract available.

PMID:
1196470
31.

Loss of active avoidance of responding after lateral hypothalamic injections of 6-hydroxydopamine.

Smith GP, Levin BE, Ervin GN.

Brain Res. 1975 May 9;88(3):483-98.

PMID:
1139290
32.

Loss of visual placing in rats after lateral hypothalamic microinjections of 6-hydroxydopamine.

Sechzer JA, Ervin GN, Smith GP.

Exp Neurol. 1973 Dec;41(3):723-37. No abstract available.

PMID:
4586282

Supplemental Content

Loading ...
Support Center